---
title: Clinical Relevance to Preclinical Methods
description: Clinical relevance in early-stage studies has the potential to increase efficiency, reduce costs, guide decisions, and enable more CNS and pain drug candidates to move forward.
---

[![mdbiosciences-logo-reversed](https://www.mdbneuro.com/hs-fs/hubfs/mdbiosciences-logo-reversed.png?width=600&height=130&name=mdbiosciences-logo-reversed.png)

![MD Biosciences Neuro logo-4](https://www.mdbneuro.com/hs-fs/hubfs/MD%20Biosciences%20Neuro%20logo-4.png?width=423&height=64&name=MD%20Biosciences%20Neuro%20logo-4.png) 

](https://www.mdbneuro.com)

[![Request Proposal](https://no-cache.hubspot.com/cta/default/42723/3821f32c-96e0-4877-b588-1e48960b10b2.png)](https://cta-redirect.hubspot.com/cta/redirect/42723/3821f32c-96e0-4877-b588-1e48960b10b2)

[**](https://www.mdbneuro.com/clinical-relevance-preclincial-methods#tmpdnd_area-module-1)

**

##### About Us

##### Webinars:

##### Cell-based Assays

##### Efficacy Models

##### Assessments

##### PK/PD & Toxicology

##### Pain

##### Neurodegeneration

##### Neuroinflammation

##### Wound Healing

##### Content

##### Whitepapers:

###### DOWNLOAD whitepaper

## STRATEGIES TO ADD CLINICAL RELEVANCE TO PRECLINICAL METHODS.

**Increase efficiency, reduce costs, guide decisions, and enable more CNS drug candidates to move forward.**

![whitepaper icon](https://www.mdbneuro.com/hs-fs/hubfs/whitepaper%20icon.png?width=300&name=whitepaper%20icon.png)

 

### Increase Translational Success of CNS Drug Candidates

The overall approval rates of CNS and pain drugs are one of the lowest in the industry. Many factors contribute to the low success rates, such as the complexity of the human brain, the lack of understanding of neurobiological mechanisms, and the difficulty in measuring appropriate clinical endpoints.

In an effort to improve the efficiency of drug development and clinical trials, focus has turned to leveraging translational science through new models, methods and biomarkers. Building connections between early stage researchers and clinicians has also paved the way for novel study designs and endpoints.

This whitepaper provides strategies for strengthening therapeutic programs and case studies that show the successful development of translational models, biomarkers and clinical endpoints.

**Complete this form for instant access to the whitepaper.**

[![mdbiosciences-logo-reversed](https://www.mdbneuro.com/hubfs/mdbiosciences-logo-reversed.png) ](https://www.mdbneuro.com)

Copyright © 2024 MD Biosciences

[**](https://www.facebook.com/mdbiosciences1/)[**](https://twitter.com/mdbneuro)[**](https://www.instagram.com/mdbneuro)[**](https://www.linkedin.com/company/mdbiosciences)

**

![](https://px.ads.linkedin.com/collect/?pid=3993628&fmt=gif)